TQA-3563

N/A

Report date: 2025/11/28 20:00:57
NME

Base Information

Drug NameTQA-3563
Drug Alias NameTQA3563TQA-3563
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCaspase inhibitors
TargetsCaspase
Therapy Area/IndicationsMetabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaPending
Originator CompaniesJiangsu Chia Tai-Tianqing Pharmaceutical Co LtdLianyungang Runzhong Pharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesN/A
Inactive CompaniesJiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd
Active IndicationsN/A
Inactive IndicationsMetabolic Dysfunction-Associated Steatotic Liver Disease

Other Information

ATC CodeN/A
Related LinksN/A